Faeth TherapeuticsFTH
13F holders, Q3 2025 (September 30)9holders −1
1new positions
2sold out
1famous investor
$9.45avg. 13F price*
At the end of Q3 2025, 9 institutions reported holding Faeth Therapeutics Inc. (FTH) in their 13F filings, down 1 from Q2 2025. 1 opened new positions and 2 sold out. The largest holders were Ikarian Capital, LLC ($213K), Catalio Capital Management, LP ($139K) and Renaissance Technologies ($98K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Faeth Therapeutics Inc.
- Filed as
- SENSEI BIOTHERAPEUTICS INC (Q3 2025)
- CUSIP
- 81728A207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $98K |
| Exits | 2 | $256K |
All 13F filers, Q2 2025 → Q3 2025: 10,464 shares bought and 31,057 shares sold, net −20,593 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Ikarian Capital, LLC | 0.04% | No change | 22,497 | $213K |
| Catalio Capital Management, LP | 0.03% | No change | 14,718 | $139K |
| Renaissance Technologies | 0.00% | New | 10,416 | $98K |
| UBS Group AG | 0.00% | Reduce -59.2% | 873 | $8K |
| Bank of America Corp. | 0.00% | Add +8.2% | 631 | $6K |
| SBI Securities Co., Ltd. | 0.00% | No change | 149 | $1K |
| JPMorgan Chase & Co. | 0.00% | No change | 32 | $302 |
| Morgan Stanley | 0.00% | No change | 10 | $95 |
| BNP Paribas Financial Markets | 0.00% | No change | 9 | $85 |
"% of holder's portfolio" is FTH's weight in each manager's 13F, not the share of Faeth Therapeutics Inc. the manager owns.